4D Molecular Therapeutics were 7% higher, at $12.40, after the company said it has entered into a strategic credit-facility agreement with Hercules Capital for up to $200 million.
The biotechnology company said that even without this facility, its cash, cash equivalents and marketable-securities position is expected to continue to fund its planned operations into the second half of 2028.
Under the terms of the agreement, 4D Molecular drew an initial $20 million at closing. An additional $30 million is available, at the company's option, through June 15, 2027, with an additional $100 million available upon its achievement of certain milestones, 4D Molecular said. The remaining $50 million available is subject to final lender approval, it said.
The company said its cash, cash equivalents and marketable securities were $458 million as of March 31.
4D Molecular also said Monday that it completed enrollment for its second Phase 3 clinical trial evaluating 4D-150 in patients with wet age-related macular degeneration. 4D-150 is a potential backbone therapy designed to provide multiyear sustained delivery of anti-VEGF biologics within the retina following a single intravitreal injection, the company said.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
June 29, 2026 10:34 ET (14:34 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.